Introduction
============

In recent years, hypofractionated radiotherapy (RT) has been integrated into standard regimens in many treatment centers. Because the presumed α/β ratio in prostate cancer is close to 1.5, a hypofractionated RT regime provides a radiobiological benefit over conventional fractionated RT.[@b1-ott-7-553] In addition, because several clinical studies have demonstrated a clear radiation dose response, reflected as an improved biochemical failure-free survival rate observed with a dose-escalated RT schedule in localized prostate cancer, a hypofractionated RT regime could offer a more convenient way to treat prostate cancer.[@b2-ott-7-553]--[@b4-ott-7-553] However, the potential toxicity that could develop in normal organs surrounding the prostate causes some concern when using a hypofractionated RT regime.[@b5-ott-7-553]

Hypofractionated helical tomotherapy using a fractionation schedule of 75 Gy at 2.5 Gy per fraction for localized prostate cancer began at our institution in January 2008. Preliminary observations of the acute and late toxicities have been reported and showed that hypofractionated helical tomotherapy is well tolerated with a favorable toxicity rate.[@b6-ott-7-553] This study reports the long-term analysis of acute and late toxicities for patients with localized prostate cancer treated with hypofractionated helical tomotherapy.

Materials and methods
=====================

Eligibility criteria for this study were histologically confirmed adenocarcinoma of the prostate, completion of definitive hypofractionated helical tomotherapy with or without androgen deprivation therapy, no previous pelvic RT, no evidence of pelvic lymph node involvement or distant metastasis, no other concomitant malignant disease, no history of inflammatory bowel disease, no previous major pelvic surgery, Eastern Cooperative Oncology Group performance status of 2 or lower, and a follow-up period of more than 6 months after helical tomotherapy. At our institution, 70 prostate cancer patients met the eligibility criteria from January 2008 through August 2013 and were enrolled in this study. The institutional review board of Kyung Hee University Medical Center approved the retrospective review and analysis of patient data for this study.

The initial evaluation for all 70 patients included determination of the American Joint Committee on Cancer, 7th edition, clinical stage; risk group according to the D'Amico risk classification; pretreatment prostate-specific antigen levels; biopsy Gleason score; percentage of positive prostate biopsies; pelvic magnetic resonance imaging (MRI); and bone scan. Additional workup with transrectal ultrasonography and abdomen computed tomography (CT) was obtained according to physician preference.

Radiotherapy
------------

All patients underwent CT simulation in the supine position after immobilization with a posterior vacuum bag and an anterior vacuum-sealed cover sheet. A rectal balloon catheter was also inserted into the rectum and inflated with 60--80 cc of air, and all patients were instructed to drink 400--600 cc water 1 hour before simulation and before every treatment session. A planning CT scan of the pelvis was obtained at 5 mm intervals from above the iliac crest through the midfemur.

The simulation CT data were transferred to Hi·Art Planning Station (TomoTherapy Inc., Madison, WI, USA) for inverse planning. Clinical target volume (CTV) 1 was the prostate gland. The seminal vesicles were CTV2 and were contoured in patients with seminal vesicle invasion on the pelvic MRI or in patients with a proposed risk of seminal vesicle involvement greater than 15%, as calculated by Roach's formula.[@b7-ott-7-553] Pelvic lymph nodes including common iliac, internal and external iliac, obturator, and presacral lymph nodes were defined as CTV3 and contoured in patients with seminal vesicle invasion on pelvic MRI and a proposed risk of occult lymph nodal involvement higher than 15%, as calculated by Roach's formula.[@b7-ott-7-553] CTV1 and CTV2 were expanded in three dimensions with a 1 cm margin to obtain planning target volumes (PTVs) 1 and 2, except at the prostate-rectal interface, where a 0.5 cm margin was used. PTV3 was defined by a 0.5 cm expansion of CTV3. Rectum, bladder, and femoral heads were contoured as organs at risk.

The prescription dose was 75 Gy in 30 fractions (2.5 Gy per fraction) for PTV1. PTV2 and PTV3 simultaneously received 63 Gy (2.1 Gy per fraction) and 54 Gy (1.8 Gy per fraction), respectively. Assuming an α/β ratio of 1.5 for prostate cancer, 75 Gy in 30 fractions can be considered to be similar to 86 Gy in 43 fractions. Each treatment plan was evaluated with a cumulative dose-volume histogram. In general, plans were considered acceptable if the PTV was covered by 95% of isodose curves and doses to normal organs were limited in their tolerances. The limits used for normal organs were no more than 25% and 5% of bladder and 20% and 5% of rectum to receive greater than 50 and 70 Gy (V50 \<25% and V70 \<5% for bladder, V50 \<20% and V70 \<5% for rectum), with a maximum dose level of 75 Gy. Planning objectives were prioritized to give the greatest importance to covering the PTV, with trying to keep radiation doses in normal structures as low as possible.

RT was performed using a TomoTherapy (TomoTherapy Inc.). Triangulation marks were used to make sure the patient did not roll and to quickly position the patient in the correct location. Before each treatment, a 3.5 megavoltage fan beam CT image was acquired, using a CT detector mounted on a ring gantry and matched to the planning CT image. If necessary, the patient position was corrected. Some patients received 6 months of androgen-deprivation therapy consisting of a daily oral administration of 50 mg bicalutamide and a 4 week interval of subcutaneous injection of a luteinizing hormone-releasing hormone analogue at the physician's discretion. RT started 8 weeks after the first injection of luteinizing hormone-releasing hormone analogue.

Toxicity evaluation
-------------------

Before the start of RT, pretreatment gastrointestinal (GI) and genitourinary (GU) symptoms were assessed according to the Common Terminology Criteria for Adverse Events, version 4.0. Patients were monitored weekly during RT and then at 2 month intervals for 1 year and at 3--4 month intervals thereafter. At each visit, GI and GU toxicities were prospectively scored by the radiation oncologist, according to Radiation Therapy Oncology Group (RTOG) criteria. Acute toxicity was defined as experiencing toxicity during or within 6 months of RT. Late toxicity was defined as any toxicity occurring or persisting 6 months or more after RT. The worst toxicity grade scored at any time was considered the final grade of toxicity.

Statistical analysis
--------------------

The Kaplan--Meier method was used to compute the actuarial incidence of toxicity. The correlation of the development of toxicity with potential predictive factors was determined using the log-rank test. Parameters evaluated as potential predictive factors for toxicity were age, RT target, androgen-deprivation therapy, pretreatment symptoms, and several dosimetric parameters. For multivariate analysis, the Cox proportional regression hazard model was used. Elapsed time was calculated from the date of RT start to the date of maximum toxicity recognition or final follow-up visit. Receiver-operating characteristic (ROC) curves were generated to define the cutoff values for significant parameters. For all analyses, a *P*-value \<0.05 was considered statistically significant. All analyses were performed using SPSS version 18.0 (IBM Corporation, Armonk, NY, USA).

Results
=======

Patient characteristics
-----------------------

All patients completed the planned RT without any interruption. All patients tolerated the rectal inflation procedure well throughout the simulation and treatment course. Five patients did not tolerate the bladder-filling procedure during the treatment course, and these patients were instructed to drink 100--200 cc water 1 hour before treatment. Characteristics of all patients are summarized in [Table 1](#t1-ott-7-553){ref-type="table"}. The median follow-up duration was 3.0 years (range, 0.7--5.8 years). Four patients (5.7%) had grade 1 pretreatment GI symptoms such as abdominal distension, anal pain, and fecal incontinence. Fifty-two (74.3%) and 5 (7.1%) patients had grade 1 and 2 pretreatment GU symptoms, respectively, such as urinary frequency, urgency, dysuria, urinary retention, and hematuria.

Radiotherapy dosimetric data
----------------------------

The radiation dose-volume relationship for PTV and normal structures was analyzed and summarized in [Table 2](#t2-ott-7-553){ref-type="table"}. In all patients, the PTV was covered by the 95% isodose curve. The dose-volume limits of normal structures were met in almost all patients, but the maximum dose limits of the normal structures were not reached and were put in to try to keep maximum doses in normal structures as low as possible.

Acute toxicity and predictive factors
-------------------------------------

The maximum RTOG acute GI toxicity scores were 0 in 36 patients (51.4%), 1 in 30 patients (42.9%), and 2 in 4 patients (5.7%). There was no grade 3 or worse acute GI toxicity, and all acute GI toxicities developed within 10 weeks after RT. The 25-week actuarial incidence rate of grade 1 or 2 acute GI toxicity was 48.6%. The most common acute GI toxicity was anal pain, and many patients experienced several acute GI toxicities simultaneously. All acute GI toxicities are summarized in [Table 3](#t3-ott-7-553){ref-type="table"}.

The maximum RTOG acute GU toxicity scores were 0 in 5 patients (7.1%), 1 in 45 patients (64.3%), and 2 in 20 patients (28.6%). There was no grade 3 or worse acute GU toxicity; however, almost all patients experienced acute GU toxicity. All acute GU toxicities developed within 10 weeks after RT, and the 25 week actuarial incidence rate of grade 1 or 2 acute GU toxicity was 92.9%. Urinary frequency developed in all patients who experienced acute GU toxicity, and many patients experienced several acute GU toxicities simultaneously. All acute GU toxicities are summarized in [Table 4](#t4-ott-7-553){ref-type="table"}.

Predictive factors for grade 1 or 2 acute GI toxicity were analyzed. Only rectum maximum dose was significantly associated with grade 1 or 2 acute GI toxicity on univariate analysis (*P*=0.042). On multivariate analysis, rectum maximum dose remained a significant predictive factor (hazard ratio =1.980; 95% confidence interval, 1.008--3.891; *P*=0.047; [Table 5](#t5-ott-7-553){ref-type="table"} and [Figure 1](#f1-ott-7-553){ref-type="fig"}). The cutoff value of rectum maximum dose by ROC curves analysis was 76.5 Gy (sensitivity, 61.8%; specificity, 69.4%). Because of the low incidence of grade 2 acute GI toxicity, we did not attempt to find predictive factors for grade 2 acute GI toxicity.

Predictive factors for grade 1 or 2 acute GU toxicity were analyzed. RT target (*P*=0.022), bladder V40 (*P*=0.038), and bladder V50 (*P*=0.040) were significantly associated with grade 1 or 2 acute GU toxicity on univariate analysis. On multivariate analysis, bladder V40 (hazard ratio =1.801; 95% confidence interval, 1.065--3.145; *P*=0.025) and bladder V50 (hazard ratio =1.814; 95% confidence interval, 1.087--3.027; *P*=0.021) remained significant predictive factors for grade 1 or 2 acute GU toxicity ([Table 6](#t6-ott-7-553){ref-type="table"}, [Figures 2](#f2-ott-7-553){ref-type="fig"} and [3](#f3-ott-7-553){ref-type="fig"}). The cutoff values of bladder V40 and V50, by ROC curves analysis, were 17.3% (sensitivity, 76.9%; specificity, 80.0%) and 10.2% (sensitivity, 70.8%; specificity, 100%), respectively.

Predictive factors for grade 2 acute GU toxicity were also analyzed. Pretreatment GU symptoms were significantly associated with grade 2 acute GU toxicity on univariate analysis (*P*=0.018). However, on multivariate analysis, no parameters were significantly associated with grade 2 acute GU toxicity ([Table 7](#t7-ott-7-553){ref-type="table"}).

Late toxicity and predictive factors
------------------------------------

Of all patients, 50 were followed-up for more than 2 years. The median follow-up duration of these 50 patients was 3.9 years (range, 2.0--5.8 years). Thirty-two (64.0%) and 9 (18.0%) patients had high- and intermediate-risk disease, respectively, and the other 9 patients (18.0%) had low-risk disease. Only 4 patients of these patients received androgen-deprivation therapy. The RT target was the prostate gland in 24 patients (48.0%), prostate gland and seminal vesicles in 18 patients (36.0%), and prostate gland, seminal vesicles, and pelvic lymph nodes in 8 patients (16.0%). Three patients (6.0%) had grade 1 pretreatment GI symptoms, and 36 (72.0%) and 3 (6.0%) patients had grade 1 and 2 pretreatment GU symptoms, respectively. Late toxicities were evaluated in these 50 patients.

The maximum RTOG late GI toxicity scores were 0 in 41 patients (82.0%), 1 in 7 patients (14.0%), and 2 in 2 patients (4.0%). There was no grade 3 or worse late GI toxicity, and the incidence of late GI toxicity seemed to reach a plateau at 24 months after treatment. The 24-month actuarial incidence rate of grade 1 or 2 late GI toxicity was 18.0%. Most common late GI toxicity was rectal bleeding. Two patients experienced grade 2 rectal bleeding, which was successfully treated with argon plasma coagulation. Four patients experienced grade 1 rectal bleeding, which stopped spontaneously without treatment. All late GI toxicities are summarized in [Table 8](#t8-ott-7-553){ref-type="table"}.

The maximum RTOG late GU toxicity scores were 0 in 9 patients (18.0%), 1 in 28 patients (56.0%), and 2 in 13 patients (26.0%). There was no grade 3 or worse late GU toxicity. All late GU toxicities developed within 23.5 months after RT, and incidence of late GU toxicity seemed to plateau at 23.5 months after treatment. The 24-months actuarial incidence rate of grade 1 or 2 late GU toxicity was 82.0%. The most common late GU toxicity was urinary frequency, which developed in all patients who experienced late GU toxicity. All late GU toxicities are summarized in [Table 9](#t9-ott-7-553){ref-type="table"}.

Predictive factors for grade 1 or 2 late GI toxicity were analyzed. Age (*P*=0.018) and pretreatment GI symptoms (*P*=0.023) were significantly associated with grade 1 or 2 late GI toxicity on univariate analysis. However, on multivariate analysis, age and pretreatment GI symptoms were not significantly associated with grade 1 or 2 late GI toxicity, and rectum V70 was a significant predictive factor (hazard ratio, 6.472; 95% confidence interval, 0.559--74.905; *P*=0.032; [Table 10](#t10-ott-7-553){ref-type="table"} and [Figure 4](#f4-ott-7-553){ref-type="fig"}). The cutoff value of rectum V70, by ROC curves analysis, was 2.8% (sensitivity, 85.6%; specificity, 71.2%). Because of the low incidence of grade 2 late GI toxicity, no attempt was made to find predictive factors for grade 2 late GI toxicity.

Predictive factors for grade 1 or 2 late GU toxicity were analyzed. Bladder V60 (*P*=0.036) and V70 (*P*=0.024) were significantly associated with grade 1 or 2 late GU toxicity on univariate analysis. On multivariate analysis, bladder V70 (hazard ratio, 1.992; 95% confidence interval, 1.068--3.718; *P*=0.030) remained a significant predictive factor ([Table 11](#t11-ott-7-553){ref-type="table"} and [Figure 5](#f5-ott-7-553){ref-type="fig"}). The cutoff value of bladder V70, by ROC curves analysis, was 2.8% (sensitivity, 68.3%; specificity, 77.8%).

Predictive factors for grade 2 late GU toxicity were also analyzed. Pretreatment GU symptoms (*P*=0.036), bladder V60 (*P*=0.034), bladder V70 (*P*=0.021), and bladder V75 (*P*=0.013) were significantly associated with grade 2 late GU toxicity on univariate analysis. On multivariate analysis, bladder V70 (hazard ratio, 4.001; 95% confidence interval, 1.165--17.364; *P*=0.034) and bladder V75 (hazard ratio, 4.417; 95% confidence interval, 1.214--16.066; *P*=0.024) remained significant predictive factors for grade 2 late GU toxicity ([Table 12](#t12-ott-7-553){ref-type="table"}, [Figures 6](#f6-ott-7-553){ref-type="fig"} and [7](#f7-ott-7-553){ref-type="fig"}). The cutoff values of bladder V70 and V75, by ROC curves analysis, were 2.8% (sensitivity, 76.9%; specificity, 66.8%) and 1.0% (sensitivity, 84.3%; specificity, 62.2%), respectively.

Discussion
==========

The results of our previous study, which analyzed radiation toxicities in 22 prostate cancer patients treated with helical tomotherapy using a fractionation schedule of 75 Gy at 2.5 Gy per fraction, showed a favorable toxicity rate.[@b6-ott-7-553] That study, however, had several limitations. The sample size was too small, and the follow-up period was not sufficiently long. As a consequence, we had difficulty making a firm conclusion. The current study analyzed the acute and late toxicities of all patients who underwent the same therapeutic regimen at our institution between January 2008 and August 2013. Because of the larger sample size and longer follow-up period, this study provided the opportunity to confirm the outcomes of our previous study.

Several studies have shown improved biochemical failure-free survival with dose-escalated RT schedules in localized prostate cancer.[@b2-ott-7-553]--[@b4-ott-7-553],[@b8-ott-7-553] Thus, greater equivalent doses should be delivered using hypofractionated RT schedules. At the Cleveland Clinic Foundation, Kupelian et al showed that 70 Gy at 2.5 Gy per fraction was given safely to patients with localized prostate cancer, using intensity-modulated radiotherapy (IMRT).[@b9-ott-7-553],[@b10-ott-7-553] Therefore, it would be possible to give more total dose than 70 Gy at 2.5 Gy per fraction without serious acute or late toxicities. Our hypofractionated helical tomotherapy schedule (total 75 Gy, 2.5 Gy per fraction) was designed to give a higher biological equivalent dose than that of the Cleveland Clinic Foundation, with an acceptable risk of serious GI and GU complications. Assuming an α/β ratio of 1.5 for prostate cancer, the total equivalent dose of our fractionation schedule would be 86 Gy if delivered at 2 Gy per fraction. The total equivalent doses of various hypofractionated RT schedules for prostate cancer from other studies ranged from 76 Gy to 82 Gy if delivered at 2 Gy per fraction.[@b9-ott-7-553],[@b11-ott-7-553]--[@b16-ott-7-553] The total equivalent dose of our fractionation schedule is higher than that of other studies. Because of the higher equivalent dose of our fractionation schedule, the accuracy of the daily patient setup was crucial. To minimize organ motion secondary to bladder or rectal filling, we inserted a rectal balloon catheter into the rectum and inflated it with 60--80 cc air, and all patients were instructed to drink 400--600 cc water 1 hour before every treatment session. Several studies have reported that rectal balloon and bladder filling can decrease daily motion variation.[@b17-ott-7-553]--[@b20-ott-7-553]

The reported incidence rate of GI and GU toxicities after hypofractionated RT for prostate cancer has varied widely.[@b9-ott-7-553],[@b11-ott-7-553]--[@b14-ott-7-553],[@b21-ott-7-553]--[@b24-ott-7-553] The reported rates of grade 0, 1, 2, and 3 acute GI toxicities ranged from 30%--66% to 22%--60%, 10%--35%, and 0%--3.5%, respectively, and those of acute GU toxicities ranged from 10%--33% to 43%--70%, 7%--40%, and 0%--8%, respectively. Inconsistencies in reported rates may be attributed to subjectivity in the scoring criteria for radiation toxicities. Because most scoring criteria for radiation toxicities are based on evaluation by the treating physician, inter- and intraobserver variation may be present. Other possible reasons for inconsistencies in the reported rates of radiation toxicities include various RT techniques and definitions of target volume, different indications for adjuvant hormonal therapy, and heterogeneous pretreatment symptoms of patient populations. In our study, there was no grade 3 or worse acute toxicity. The incidences of grade 0, 1, and 2 acute GI toxicity were 51.4%, 42.9%, and 5.7%, and those of acute GU toxicity were 7.1%, 64.3%, and 28.6%, respectively. Compared with previous reports, our study generally showed comparable toxicity rates; however, the rate of grade 2 acute GI toxicity was markedly lower (10%--35% versus 5.7%). In contrast, the reported rates of grade 0, 1, 2, and 3 late GI toxicities ranged from 66%--93% to 2%--27%, 3%--17%, and 0%--7%, and those of late GU toxicities ranged from 46%--90% to 4%--43%, 0%--17%, and 0%--4%, respectively. In our study, the incidences of grade 0, 1, and 2 late GI toxicity were 82.0%, 14.0%, and 4.0%, and those of late GU toxicity were 18.0%, 56.0%, and 26.0%, respectively. Our study showed comparable or favorable late GI toxicity rates compared with previous reports. However, our study showed unfavorable late GU toxicity rates. In our study, the rate of grade 0 late GU toxicity was lower (46%--90% versus 18%) and the rates of grade 1 (4%--43% versus 56%) and 2 (0%--17% versus 26%) late GU toxicities were higher than previous reports. However, all patients tolerated the treatment course and follow-up period well throughout, and our study showed no grade 3 or worse late GU toxicity. Therefore, taken altogether, the late GU toxicity rates of this study seemed to be acceptable ([Table 13](#t13-ott-7-553){ref-type="table"}).

To our knowledge, no published study has analyzed predictive factors for radiation toxicities after helical tomotherapy in prostate cancer. Kupelian et al[@b21-ott-7-553] reported that rectum V70 was a significant predicting factor for grade 2 or 3 late rectal toxicity after linac-based IMRT, and Huang et al[@b25-ott-7-553] reported that rectum V60, V70, and V78 were significantly associated with grade 2 or 3 late rectal toxicity after three-dimensional conformal RT. However, because a large volume of normal tissue is exposed to low-dose radiation during helical tomotherapy, predictive factors for radiation toxicity after helical tomotherapy may differ from those after 3-dimensional conformal RT or linac-based IMRT in prostate cancer. In our study, several parameters were evaluated as potential predictive factors for acute GI and GU and for late GI and GU toxicities. Among the several parameters, rectum maximum dose (cutoff value, 76.5 Gy) was a significant predictive factor for grade 1 or 2 acute GI toxicity. In addition, bladder V40 (cutoff value, 17.3%) and V50 (cutoff value, 10.2%) for grade 1 or 2 acute GU toxicity, rectum V70 (cutoff value, 2.8%) for grade 1 or 2 late GI toxicity, bladder V70 (cutoff value, 2.8%) for grade 1 or 2 late GU toxicity, and bladder V70 (cutoff value, 2.8%) and V75 (cutoff value, 1.0%) were significant predictive factors for grade 2 late GU toxicity. Therefore, we propose constraining the rectum maximum dose to less than 76.5 Gy, rectum V70 to less than 2.8%, bladder V40 to less than 17.3%, bladder V50 to less than 10.2%, bladder V70 to less than 2.8%, and bladder V75 to less than 1.0% to reduce the development of radiation toxicity after helical tomotherapy in prostate cancer.

There were some limitations in this study. First, this study was retrospective and may have inherent bias. However, all toxicities were scored prospectively, and therefore, selection and reporting bias were limited. Second, although the sample size of this study was larger than our previous study, it was still small. Third, the patient characteristics were heterogeneous. Fourth, because of incomplete patient medical records, we could not analyze the incidence of radiation-induced erectile dysfunction. Despite these limitations, if additional studies show favorable tumor control and survival rates in prostate cancer patients treated with our fractionation regimen, hypofractionated helical tomotherapy using a fractionation schedule of 75 Gy at 2.5 Gy per fraction could be a safe and effective way of dose escalation in treating localized prostate cancer.

Conclusion
==========

With a long follow-up period, hypofractionated helical tomotherapy using a fractionation schedule of 75 Gy at 2.5 Gy per fraction showed favorable acute and late toxicity rates and no serious complications, such as grade 3 or worse toxicity. To minimize radiation toxicities, rectum maximum dose, rectum V70, and bladder V40, V50, V70, and V75 should be kept as low as possible. In addition, further studies are necessary to analyze the tumor control and survival rates in prostate cancer patients treated with hypofractionated helical tomotherapy, using a fractionation schedule of 75 Gy at 2.5 Gy per fraction.
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![Incidence of grade 1 or 2 acute genitourinary toxicity according to bladder V40. The 25-week actuarial rate of grade 1 or 2 acute genitourinary toxicity was 85.7% if V40 was 24% or lower and 100% if V40 was higher than 24% (*P*=0.038 on univariate and *P*=0.025 on multivariate analysis).](ott-7-553Fig2){#f2-ott-7-553}
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###### 

Patient characteristics (n=70)

  Characteristics                                               n (%)
  ------------------------------------------------------------- -------------------
  Age, years, median (range)                                    72.3 (54.2--82.1)
  Pre-RT PSA, ng/mL, median (range)                             13.5 (3.2--235.6)
  Gleason score                                                 
   3+3                                                          27 (38.6%)
   3+4                                                          13 (18.6%)
   4+3                                                          10 (14.2%)
   4+4                                                          7 (10.0%)
   4+5                                                          8 (11.4%)
   5+4                                                          4 (5.7%)
   5+5                                                          1 (1.5%)
  Percentage of positive prostate biopsies, %, median (range)   42.3 (8.3--100.0)
  T stage                                                       
   1c                                                           19 (27.1%)
   2a                                                           1 (1.6%)
   2b                                                           12 (17.1%)
   2c                                                           5 (7.1%)
   3a                                                           14 (20.0%)
   3b                                                           19 (27.1%)
  Risk group                                                    
   Low                                                          10 (14.3%)
   Intermediate                                                 14 (20.0%)
   High                                                         46 (65.7%)
  RT target                                                     
   PG                                                           39 (55.7%)
   PG + SV                                                      22 (31.4%)
   PG + SV + PLN                                                9 (12.9%)
  Androgen-deprivation therapy                                  
   Yes                                                          16 (22.9%)
   No                                                           54 (77.1%)
  Pretreatment gastrointestinal symptoms                        
   Grade 0                                                      66 (94.3%)
   Grade 1                                                      4 (5.7%)
  Pretreatment genitourinary symptoms                           
   Grade 0                                                      13 (18.6%)
   Grade 1                                                      52 (74.3%)
   Grade 2                                                      5 (7.1%)

**Abbreviations:** RT, radiotherapy; PSA, prostate-specific antigen; PG, prostate gland; SV, seminal vesicles; PLN, pelvic lymph nodes.

###### 

Dosimetric data of hypofractionated helical tomotherapy for whole patients (n=70)

  Dosimetric parameters   Median (range)
  ----------------------- --------------------
  PTV1                    
   Mean dose, Gy          75.7 (75.4--78.6)
   Maximum dose, Gy       77.7 (77.2--81.5)
   Minimum dose, Gy       73.1 (73.6--75.6)
  PTV2                    
   Mean dose, Gy          67.7 (63.3--70.5)
   Maximum dose, Gy       76.0 (68.8--77.8)
   Minimum dose, Gy       61.4 (52.3--64.4)
  PTV3                    
   Mean dose, Gy          57.7 (54.8--61.7)
   Maximum dose, Gy       69.6 (60.4--79.2)
   Minimum dose, Gy       50.4 (46.2--53.1)
  Rectum                  
   V5, %                  93.8 (65.0--100.0)
   V10, %                 87.3 (58.0--100.0)
   V20, %                 74.5 (42.3--98.0)
   V30, %                 48.6 (24.5--93.2)
   V40, %                 27.0 (15.0--64.1)
   V50, %                 15.0 (8.2--28.2)
   V60, %                 7.9 (4.6--14.3)
   V70, %                 3.0 (1.0--8.7)
   V75, %                 1.0 (0.1--5.6)
   Maximum dose, Gy       76.5 (75.6--79.7)
  Bladder                 
   V5, %                  82.2 (18.0--100.0)
   V10, %                 71.5 (9.3--100.0)
   V20, %                 57.5 (10.7--99.5)
   V30, %                 40.5 (7.2--82.5)
   V40, %                 24.5 (3.0--50.0)
   V50, %                 14.3 (1.4--40.0)
   V60, %                 8.0 (0.6--29.1)
   V70, %                 3.0 (0.1--16.4)
   V75, %                 1.1 (0--10.5)
   Maximum dose, Gy       76.7 (74.9--80.6)

**Abbreviation:** PTV, planning target volume.

###### 

Acute gastrointestinal toxicities (n=70)

  Maximum grade and specific toxicities   n (%)
  --------------------------------------- -----------
  Grade 0                                 36 (51.4)
  Grade 1                                 30 (42.9)
   Anal pain                              25 (35.7)
   Rectal bleeding                        5 (7.1)
   Diarrhea                               2 (2.9)
   Constipation                           2 (2.9)
   Fecal incontinence                     2 (2.9)
  Grade 2                                 4 (5.7)
   Anal pain                              3 (4.3)
   Diarrhea                               1 (1.4)
   Fecal incontinence                     1 (1.4)

###### 

Acute genitourinary toxicities (n=70)

  Maximum grade and specific toxicities   n (%)
  --------------------------------------- -----------
  Grade 0                                 5 (7.1)
  Grade 1                                 45 (64.3)
   Urinary frequency                      45 (64.3)
   Urinary urgency                        11 (15.7)
   Dysuria                                8 (11.4)
   Urinary retention                      5 (7.1)
   Urinary incontinence                   4 (5.7)
  Grade 2                                 20 (28.6)
   Urinary frequency                      20 (28.6)
   Urinary urgency                        6 (8.6)
   Dysuria                                3 (4.3)
   Urinary incontinence                   1 (1.4)

###### 

Analysis of predictive factors for grade 1 or 2 acute gastrointestinal toxicity

  Variables                                           25-week actuarial rate of grade 1 or 2 acute GI toxicity, %   *P*-value   
  --------------------------------------------------- ------------------------------------------------------------- ----------- -------
  Age, years, ≤70 versus \>70                         58.3 versus 43.5                                              0.352       0.385
  RT target, PG versus PG + SV versus PG + SV + PLN   46.2 versus 45.5 versus 66.7                                  0.474       0.499
  Androgen-deprivation therapy, yes versus no         25.0 versus 55.6                                              0.097       0.096
  Pretreatment GI symptoms, yes versus no             50.0 versus 25.0                                              0.416       0.394
  Rectum                                                                                                                        
   V5 ≤93% versus \>93%                               38.2 versus 58.3                                              0.138       0.232
   V10 ≤87% versus \>87%                              41.9 versus 53.8                                              0.419       0.498
   V20 ≤75% versus \>75%                              38.5 versus 61.3                                              0.105       0.222
   V30 ≤48% versus \>48%                              41.2 versus 55.6                                              0.502       0.418
   V40 ≤27% versus \>27%                              40.5 versus 57.6                                              0.275       0.391
   V50 ≤15% versus \>15%                              45.0 versus 53.3                                              0.700       0.757
   V60 ≤8% versus \>8%                                47.2 versus 50.0                                              0.996       0.969
   V70 ≤3% versus \>3%                                45.7 versus 51.4                                              0.705       0.967
   V75 ≤1% versus \>1%                                40.0 versus 57.1                                              0.184       0.450
   Max dose ≤76.5 Gy versus \>76.5 Gy                 40.5 versus 60.7                                              0.042       0.047

**Abbreviations:** RT, radiotherapy; PG, prostate gland; SV, seminal vesicles; PLN, pelvic lymph nodes; GI, gastrointestinal; Max dose, maximum dose.

###### 

Analysis of predictive factors for grade 1 or 2 acute genitourinary toxicity

  Variables                                           25-week actuarial rate of grade 1 or 2 acute GU toxicity, %   *P*-value   
  --------------------------------------------------- ------------------------------------------------------------- ----------- -------
  Age, years, ≤70 versus \>70                         86.5 versus 95.0                                              0.867       0.532
  RT target, PG versus PG + SV versus PG + SV + PLN   87.2 versus 100 versus 100                                    0.022       0.103
  Androgen-deprivation therapy, yes versus no         87.8 versus 94.4                                              0.913       0.695
  Pretreatment GU symptoms, yes versus no             94.7 versus 84.6                                              0.087       0.099
  Bladder                                                                                                                       
   V5 ≤82% versus \>82%                               85.7 versus 100                                               0.231       0.328
   V10 ≤71% versus \>71%                              85.7 versus 100                                               0.318       0.345
   V20 ≤57% versus \>57%                              85.7 versus 100                                               0.251       0.332
   V30 ≤40% versus \>40%                              85.7 versus 100                                               0.084       0.056
   V40 ≤24% versus \>24%                              85.7 versus 100                                               0.038       0.025
   V50 ≤14% versus \>14%                              83.9 versus 100                                               0.040       0.021
   V60 ≤8% versus \>8%                                86.8 versus 100                                               0.118       0.112
   V70 ≤3% versus \>3%                                89.7 versus 96.8                                              0.573       0.381
   V75 ≤1% versus \>1%                                90.9 versus 94.6                                              0.845       0.694
   Max dose ≤76.7 Gy versus \>76.7 Gy                 89.7 versus 96.8                                              0.254       0.500

**Abbreviations:** RT, radiotherapy; PG, prostate gland; SV, seminal vesicles; PLN, pelvic lymph nodes; GU, genitourinary; Max dose, maximum dose.

###### 

Analysis of predictive factors for grade 2 acute genitourinary toxicity

  Variables                                           25-week actuarial rate of grade 2 acute GU toxicity, %   *P*-value   
  --------------------------------------------------- -------------------------------------------------------- ----------- -------
  Age, years, ≤70 versus \>70                         29.2 versus 28.3                                         0.863       0.911
  RT target, PG versus PG + SV versus PG + SV + PLN   25.6 versus 22.7 versus 55.6                             0.102       0.171
  Androgen-deprivation therapy, yes versus no         31.2 versus 27.8                                         0.733       0.879
  Pretreatment GU symptoms, yes versus no             35.1 versus 0                                            0.018       0.147
  Bladder                                                                                                                  
   V5 ≤82% versus \>82%                               22.9 versus 34.3                                         0.339       0.605
   V10 ≤71% versus \>71%                              22.9 versus 34.3                                         0.339       0.408
   V20 ≤57% versus \>57%                              22.9 versus 34.3                                         0.334       0.479
   V30 ≤40% versus \>40%                              22.9 versus 34.3                                         0.318       0.568
   V40 ≤24% versus \>24%                              22.9 versus 34.3                                         0.299       0.796
   V50 ≤14% versus \>14%                              19.4 versus 35.9                                         0.140       0.555
   V60 ≤8% versus \>8%                                21.1 versus 37.5                                         0.131       0.404
   V70 ≤3% versus \>3%                                25.6 versus 32.3                                         0.544       0.951
   V75 ≤1% versus \>1%                                24.2 versus 32.4                                         0.517       0.803
   Max dose ≤76.7 Gy versus \>76.7 Gy                 20.5 versus 38.7                                         0.109       0.262

**Abbreviations:** RT, radiotherapy; PG, prostate gland; SV, seminal vesicles; PLN, pelvic lymph nodes; GU, genitourinary; Max dose, maximum dose.

###### 

Late gastrointestinal toxicities in patients followed-up for more than 2 years (n=50)

  Maximum grade and specific toxicities   n (%)
  --------------------------------------- -----------
  Grade 0                                 41 (82.0)
  Grade 1                                 7 (14.0)
   Rectal bleeding                        4 (8.0)
   Proctitis                              4 (8.0)
   Rectal ulcer                           2 (4.0)
   Fecal incontinence                     1 (2.0)
  Grade 2                                 2 (4.0)
   Rectal bleeding                        2 (4.0)
   Proctitis                              2 (4.0)
   Rectal ulcer                           1 (2.0)
   Rectal telangiectasia                  1 (2.0)

###### 

Late genitourinary toxicities in patients followed-up for more than 2 years (n=50)

  Maximum grade and specific toxicities   n (%)
  --------------------------------------- -----------
  Grade 0                                 9 (18.0)
  Grade 1                                 28 (56.0)
   Urinary frequency                      28 (56.0)
   Urinary urgency                        7 (14.0)
   Urinary incontinence                   5 (10.0)
   Dysuria                                2 (4.0)
   Urinary retention                      1 (2.0)
  Grade 2                                 13 (26.0)
   Urinary frequency                      13 (26.0)
   Urinary incontinence                   8 (16.0)
   Urinary urgency                        3 (6.0)

###### 

Analysis of predictive factors for grade 1 or 2 late gastrointestinal toxicity

  Variables                                           24-month actuarial rate of grade 1 or 2 late GI toxicity, %   *P*-value   
  --------------------------------------------------- ------------------------------------------------------------- ----------- -------
  Age, years, ≤70 versus \>70                         0 versus 30.0                                                 0.018       0.717
  RT target, PG versus PG + SV versus PG + SV + PLN   0 versus 11.1 versus 29.2                                     0.143       0.159
  Androgen deprivation therapy, yes versus no         19.6 versus 0                                                 0.354       0.931
  Pretreatment GI symptoms, yes versus no             66.7 versus 14.9                                              0.023       0.869
  Rectum                                                                                                                        
   V5 ≤95% versus \>95%                               8.7 versus 25.9                                               0.120       0.973
   V10 ≤90% versus \>90%                              8.7 versus 25.9                                               0.120       0.983
   V20 ≤79% versus \>79%                              8.0 versus 28.0                                               0.064       0.915
   V30 ≤50% versus \>50%                              16.7 versus 19.2                                              0.863       0.393
   V40 ≤27% versus \>27%                              13.6 versus 21.4                                              0.454       0.829
   V50 ≤15% versus \>15%                              16.0 versus 20.0                                              0.682       0.610
   V60 ≤8% versus \>8%                                13.8 versus 23.8                                              0.341       0.078
   V70 ≤3% versus \>3%                                11.1 versus 26.1                                              0.149       0.032
   V75 ≤1% versus \>1%                                17.4 versus 18.5                                              0.932       0.135
   Max dose ≤76.7 Gy versus \>76.7 Gy                 16.0 versus 20.0                                              0.793       0.483

**Abbreviations:** RT, radiotherapy; PG, prostate gland; SV, seminal vesicles; PLN, pelvic lymph nodes; GI, gastrointestinal; Max dose, maximum dose.

###### 

Analysis of predictive factors for grade 1 or 2 late genitourinary toxicity

  Variables                                           24-month actuarial rate of grade 1 or 2 late GU toxicity, %   *P*-value   
  --------------------------------------------------- ------------------------------------------------------------- ----------- -------
  Age, years, ≤70 versus \>70                         80.0 versus 83.3                                              0.642       0.836
  RT target, PG versus PG + SV versus PG + SV + PLN   75.0 versus 83.3 versus 100                                   0.428       0.230
  Androgen-deprivation therapy, yes versus no         100 versus 80.4                                               0.107       0.117
  Pretreatment GU symptoms, yes versus no             87.2 versus 63.6                                              0.092       0.099
  Bladder                                                                                                                       
   V5 ≤85% versus \>85%                               73.1 versus 91.7                                              0.071       0.078
   V10 ≤75% versus \>75%                              73.1 versus 91.7                                              0.100       0.108
   V20 ≤61% versus \>61%                              72.0 versus 92.0                                              0.076       0.083
   V30 ≤44% versus \>44%                              76.0 versus 88.0                                              0.334       0.346
   V40 ≤27% versus \>27%                              76.9 versus 87.5                                              0.327       0.339
   V50 ≤15% versus \>15%                              73.1 versus 91.7                                              0.081       0.089
   V60 ≤8% versus \>8%                                74.1 versus 91.3                                              0.036       0.051
   V70 ≤3% versus \>3%                                71.4 versus 95.5                                              0.024       0.030
   V75 ≤1% versus \>1%                                73.1 versus 91.7                                              0.111       0.120
   Max dose ≤76.9 Gy versus \>76.9 Gy                 72.0 versus 92.0                                              0.054       0.060

**Abbreviations:** RT, radiotherapy; PG, prostate gland; SV, seminal vesicles; PLN, pelvic lymph nodes; GU, genitourinary; Max dose, maximum dose.

###### 

Analysis of predictive factors for grade 2 late genitourinary toxicity

  Variables                                           24-month actuarial rate of grade 2 late GU toxicity, %   *P*-value   
  --------------------------------------------------- -------------------------------------------------------- ----------- -------
  Age, years, ≤70 versus \>70                         20.0 versus 35.0                                         0.214       0.162
  RT target, PG versus PG + SV versus PG + SV + PLN   16.7 versus 29.2 versus 37.5                             0.533       0.991
  Androgen-deprivation therapy, yes versus no         50 versus 23.9                                           0.182       0.181
  Pretreatment GU symptoms, yes versus no             33.3 versus 0                                            0.036       0.093
  Bladder                                                                                                                  
   V5 ≤85% versus \>85%                               23.1 versus 29.2                                         0.630       0.704
   V10 ≤75% versus \>75%                              23.1 versus 29.2                                         0.630       0.894
   V20 ≤61% versus \>61%                              20.0 versus 32.0                                         0.315       0.703
   V30 ≤44% versus \>44%                              20.0 versus 32.0                                         0.315       0.703
   V40 ≤27% versus \>27%                              19.2 versus 33.3                                         0.212       0.489
   V50 ≤15% versus \>15%                              19.2 versus 33.3                                         0.212       0.810
   V60 ≤8% versus \>8%                                14.8 versus 39.1                                         0.034       0.254
   V70 ≤3% versus \>3%                                14.3 versus 40.9                                         0.021       0.034
   V75 ≤1% versus \>1%                                11.5 versus 41.7                                         0.013       0.024
   Max dose ≤76.9 Gy versus \>76.9 Gy                 20.0 versus 30.0                                         0.259       0.667

**Abbreviations:** RT, radiotherapy; PG, prostate gland; SV, seminal vesicles; PLN, pelvic lymph nodes; GU, genitourinary; Max dose, maximum dose.

###### 

Comparison of reported toxicity rates between previous studies and our study

  Grade                                     Previous studies   Our study
  ----------------------------------------- ------------------ -----------
  Acute gastrointestinal toxicity rate, %                      
   0                                        30--66             51.4
   1                                        22--60             42.9
   2                                        10--35             5.7
   3                                        0--3.5             0
  Acute genitourinary toxicity rate, %                         
   0                                        10--33             7.1
   1                                        43--70             64.3
   2                                        7--40              28.6
   3                                        0--8               0
  Late gastrointestinal toxicity rate, %                       
   0                                        66--93             82.0
   1                                        2--27              14.0
   2                                        3--17              4.0
   3                                        0--7               0
  Late genitourinary toxicity rate, %                          
   0                                        46--90             18.0
   1                                        4--43              56.0
   2                                        0--17              26.0
   3                                        0--4               0
